Bmi-1-targeting suppresses osteosarcoma aggressiveness through the NF-κB signaling pathway

Documenti analoghi

• Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-κB signaling pathway
  di: Li, Yi-Jiong, et al.
  Pubblicazione: (2018)
• Punicalagin inhibited proliferation, invasion and angiogenesis of osteosarcoma through suppression of NF-κB signaling
  di: Huang, Tao, et al.
  Pubblicazione: (2020)
• Papaverine inhibits lipopolysaccharide-induced microglial activation by suppressing NF-κB signaling pathway
  di: Dang, Yalong, et al.
  Pubblicazione: (2016)
• 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks
  di: Li, Weixu, et al.
  Pubblicazione: (2020)
• Anti-Neuroinflammatory Effect of Alantolactone through the Suppression of the NF-κB and MAPK Signaling Pathways
  di: Tan, Liwei, et al.
  Pubblicazione: (2019)